News

Ana is one of only 10 undergraduate students selected from the College of Charleston for the B.L.O.C.K.S. (Building Learning Opportunities for Cancer, Knowledge, and Success) program. She will be gaining valuable experience and knowledge in our lab. Congratulations to her!

Our PI, Dr. Ozgur Sahin, has accepted the position of Program Director of Science Translation for the Hollings Advisory for Rapid Translation (HART). In this newly created role, he will lead and support strategic initiatives to advance the translation of basic science into investigator-initiated clinical research. We sincerely congratulate him Read more

PhD candidate Kubra was awarded the Hollings Fellowship for her research titled “Targeting Triple-Negative Breast Cancer with High Chromosomal Instability.”

Congratulations to Kubra on receiving a travel award to present her research at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2025 in Boston, MA.

Kubra presented a poster entitled “Targeting TACC3 inhibits metastasis in breast cancer with centrosome amplification“. Ozge presented a poster entitled “LINC00152-regulated PDE4D mediates drug resistance and metastasis in highly aggressive breast cancer“.

Baris has been accepted into the Graduate Program at MUSC, wishing him great success in his doctoral journey.

“Hollings team marks milestone in progress toward investigational new drug for triple-negative breast cancer” https://hollingscancercenter.musc.edu/news/archive/2024/07/22/lox-inhibitor-for-triple-negative-breast-cancer

A highly potent bi-thiazole inhibitor of LOX rewires collagen architecture and enhances chemoresponse in triple-negative breast cancer https://www.sciencedirect.com/science/article/pii/S2451945624002733?via%3Dihub

We participated in the AACR conference with three distinct poster presentations.

Ozgur Sahin was recognized for his work and article, “Toxic PARP trapping upon cAMP-induced DNA damage reinstates the efficacy of endocrine therapy and CDK4/6 inhibitors in treatment-refractory ER+ breast cancer,” published by Nature Communications Nov. 2, 2023. https://medicine.musc.edu/research/excellence-awards